Diagnostic assessment of recurrent unexplained syncope with a new subcutaneously implantable loop recorder. Reveal-Investigators.

AIM: Patients with recurrent syncope undiagnosed after extensive non-invasive and invasive testing pose a diagnostic and therapeutic dilemma. Holter monitoring is nondiagnostic in 90% of cases. Recent developments in loop recorder technology permit long-term ECG monitoring in patients with recurrent unexplained syncope. The aim of this study was to report the worldwide experience with a new subcutaneously implantable loop recorder, implanted in 133 patients with unexplained syncope and negative laboratory investigations. METHODS AND RESULTS: The implantable loop recorder monitors continuously a single lead electrogram using two sensing electrodes on the device shell. The device was implanted in 133 patients, 67 male and 66 female with recurrent syncope. During a mean follow-up of 10.8 +/- 4.3 months after device implantation, 83 patients (62%) experienced syncope or pre-syncope. In the remaining 50 patients no diagnosis could be made because either no events occurred, the patients were lost to follow-up, had adverse events, or died prior to diagnosis. In 72 of the 83 patients with syncope during follow-up (87%), loop recording definitively determined whether an arrhythmia was the cause of symptoms or not. Diagnosis included bradycardia in 21 patients, pacemaker dysfunction in one patient, and tachycardia in 10 patients. One patient experienced multiple rhythm disturbances. Syncope was non-arrhythmic in 40 patients. The remaining 11 patients failed to press the activator. Therapy was instituted in all patients, in whom an arrhythmic cause was found. Severe anticipated device related complications occurred in three patients. CONCLUSION: An implantable loop recorder is useful for establishing a diagnosis when symptoms are recurrent but too infrequent for conventional monitoring techniques.     

Predictive value of presyncope in patients monitored for assessment of syncope

BACKGROUND: The purpose of this study was to assess the diagnostic value of recording the cardiac rhythm during presyncope in patients undergoing monitoring for undiagnosed syncope. METHODS AND RESULTS: Eighty-five patients (age, 59 +/- 18 years; 44 men, 41 women) with recurrent unexplained syncope underwent prolonged monitoring with an implantable loop recorder. Patients were examined for syncope, which was either recurrent or associated with at least 2 presyncopal episodes. Patients had a mean of 5.1 +/- 5.5 syncopal episodes in the previous 12 months, and 70% of patients had symptoms for >2 years. Sixty-two (73%) patients had recurrent symptoms during a 12-month follow-up period. Of 150 recurrent events captured by the implantable loop recorder, there were 38 (25%) episodes of syncope and 112 (75%) episodes of presyncope. Syncope alone recurred in 12 patients, presyncope in 25, and both in 16. An arrhythmia was present in 64% of syncopal events (bradycardia in 16, tachycardia in 2) versus 25% for presyncopal events (bradycardia in 7, tachycardia in 3, P =.001). An arrhythmia was detected in 9 (56%) of the 16 patients with both syncope and presyncope, which was present in all recorded episodes of syncope compared with 6 of 9 presyncopal episodes. Patient-related failure to freeze the device after symptoms occurred in 21 (36%) of 59 syncopal events compared with 15 (12%) of 127 presyncopal events (P =.0001). CONCLUSIONS: Syncope is more likely to be associated with an arrhythmia than is presyncope in patients undergoing extended monitoring. Presyncope is a nonspecific end point that is frequently associated with sinus rhythm. Patients undergoing extended monitoring for syncope should continue to be monitored after an episode of presyncope unless an arrhythmia is detected.     

CP25: IMPLANTABLE LOOP RECORDER FOR THE EVALUATION OF UNEXPLAINED SYNCOPE: DIAGMOSTIC CONTRIBUTION OF THE AUTOMATIC AND OF MANUAL ACTIVATION OF THE DEVICE

AIM: Our experience with implantable loop recorder (ILR) for patients(pts) with unexplained syncope is reported, focusing on therelative diagnostic contribution of the manual and the automaticactivation of the device. METHODS: According to the European Society of Cardiology Guidelines onSyncope, an ILR was reserved to: a) pts with structural heartdisease and syncope unexplained after a complete diagnosticworkup; b) pts without heart disease but with recurrent, severesyncope. Pts implanted with an ILR underwent elective controlsevery four months; further, urgent controls were planned inthe case of syncope recurrence. RESULTS: Between 15/11/02 and 22/11/04, 14 pts (M/F 4/9, age 779, 8with heart disease) were implanted with an ILR. After a 77months follow-up, 25 elective and 5 urgent controls were performed.Among the 5 pts with syncope recurrence, only 2 were able tomanually activate the device, and in both cases a bradyarrhythmiawas detected. In further 2 pts the mechanism of syncope wasdetected by the automatic activation of the device correspondingto the spontaneous symptoms. During the elective controls further239 automatic activations were detected, but none of these wasdiagnostic. CONCLUSIONS: The findings from ILR were useful only in the case of symptomrecurrence during the monitoring period, while the automaticactivation in absence of symptoms was totally useless. Nevertheless,this latter function of the device was clinically relevant giventhe low patients' ability to manually activate the device aftera spontaneous clinical event.     

Usefulness of the implantable subcutaneous recorder in the diagnosis of recurrent syncope of unknown etiology in patients without structural heart disease and negative tilt test and electrophysiological study

BACKGROUND AND OBJECTIVES: In up to 38% of the cases, the etiology of syncope difficult to determine. The main obstacle for diagnosis of the causes of syncope lies in the unpredictable frequency of episodes. Development of implantable loop recorders allows long term electrocardiographic monitoring. The aim of this study was to evaluate the usefulness of the implantable loop recorder for the diagnosis of recurrent syncope of unknown origin. PATIENTS AND METHODS: From May 1991 to April 1999, a cohort of 176 patients with recurrent syncope was prospectively assessed. Investigations, including Holter monitoring, Tilt Test and electrophysiological study, allowed the determination of the etiology in 161 patients. The remaining 15 patients, without structural cardiac disease were selected for continuous electrocardiographic monitoring using an implantable loop recorder. RESULTS: During follow up after implant, 15 +/- 2 months (X- +/- SEM), 9 patients showed recurrence of symptoms concordant with prior episodes (time: 105 +/- 30 days). In 7 cases records during symptoms were diagnostic (0.47; CI 95%: 0.21-0.73), in 3 cases a diagnosis with documented arrhythmia was achieved, and in 4 other cases a presumptive clinical diagnosis of non-arrhythmic cause was made. In 8 patients, 6 with no recurrences, diagnosis was not possible. There were no complications related to the use of the device. CONCLUSIONS: The strategy of long term monitoring with the implantable loop recorder is safe and effective in patients with recurrent syncope of unknown etiology.     

Event-Rekorder

Event or loop recorders monitor heart rhythm using discontinuous ECG storage which enables them to obtain a correlation between symptoms and the underlying heart rhythm in patients with infrequent, short-lasting episodes. External event recorders with intermittent monitoring, i.e., with electrodes within the device, are suitable for patients with palpitations or tachycardia who remain conscious. External event recorders with continuous monitoring are tolerated by patients for a few weeks and have a limited diagnostic impact in patients with recurrent syncope. The implantable loop recorder (ILR) monitors heart rhythm for one year and after patient-triggered or automatic activation stores a one-lead ECG up to 42 minutes prior to device activation. The diagnostic benefit of ILR in comparison to conventional approaches has been demonstrated in randomised studies. Furthermore, an ILR identifies patients with recurrent syncope of unknown origin in whom a pacemaker implantation can avoid further episodes. Additional possible indications are the monitoring of atrial fibrillation, the diagnostics of infrequent palpitations and patients with seizures.     

Optimal duration of monitoring in patients with unexplained syncope

The optimal duration of monitoring of patients with recurrent unexplained syncope who undergo prolonged monitoring with an implantable loop recorder is unknown. We examined the probability of syncope in a group of 167 patients with this condition who underwent prolonged monitoring with an implantable loop recorder. A 12-month monitoring period appears to capture >90% of episodes. Syncope is most likely to occur in younger patients with less heart disease and more frequent syncope. There is a low risk of syncope after 1 year of monitoring without an event.     

Value of the implantable loop recorder for the management of patients with unexplained syncope.

AIM: Recurrent syncope often remains unexplained despite extensive multidisciplinary screening. The implantable loop recorder (ILR) may be a tool to define the cardiac arrhythmias underlying syncope. METHODS AND RESULTS: The study population consisted of 43 consecutive patients with unexplained syncope who underwent extensive cardiological screening and were followed with an ILR. During follow-up, 5 patients had only presyncope, 4 had palpitations, and 15 had a true recurrence of syncope. In all patients with palpitations, 3 with presyncope, and 7 with a recurrence of syncope, the ILR excluded arrhythmias. In the patients with a true recurrence, 1 had symptomatic paroxysmal atrial fibrillation (PAF) treated with drugs, 1 had polymorphic ventricular tachycardia (VT) and received an implantable cardioverter defibrillator (ICD), and 7 had asystole and received a pacemaker. Two patients with presyncope received a pacemaker for Mobitz II block and PAF with brady-tachycardia syndrome. One asymptomatic patient received a pacemaker for significant nocturnal asystole recorded by ILR. Abnormalities in the cardiac screening were observed both in patients with and without syncope, but none of these had a predictive value. CONCLUSION: The ILR is a valuable and effective tool to establish an arrhythmic cause for unexplained syncope. The results of head-up tilt testing (HUTT) and electrophysiological study (EPS) are neither sufficiently sensitive nor specific enough in this patient group.     

Revealing data retrieved from an implantable loop recorder

This patient is an 80-year-old man with a history of recurrent syncope of unknown etiology who underwent an extensive cardiac and neurologic evaluation which was essentially negative. The patient subsequently received an implantable loop recorder (Reveal , Medtronic, Inc., Minneapolis, Minnesota). Eight months after implantation, this device was activated by the patient following a syncopal episode. The episode revealed over 30 seconds of sinus arrest with only 3 ventricular escape complexes observed during that time. The patient activated this device and was subsequently referred for a dual chamber permanent pacemaker, which was implanted without complications. This case illustrates the advantages of a non-vascular, implantable loop recorder for helping to define the etiology of recurrent unexplained syncope.     

置入式Holter诊断不明原因晕厥的应用研究

目的探讨置入式Holter(ILR)在诊断不明原因晕厥和指导治疗中的临床价值。方法入选2002年10月至2005年5月求治的不明原因晕厥患者10例,男性4例,女性6例,平均年龄(41±22)岁。有2次以上晕厥或近似晕厥史平均为(4.5±1.4)次/例,经常规检查未能明确晕厥原因。均选用Medtronic公司RevealPlus(9526型ILR。结果10例患者平均随访(17.8±6.6)个月,ILR有效监测时间平均(15.3±3.6)个月,监测期内6例患者再发晕厥或近似晕厥24次。7例患者手动触发19段心电图,ILR自动触发记录460段心电图,共记录211段心电图为心律失常事件。根据症状-心律相关性,7例患者明确为心律失常性晕厥,1例患者明确为非心律失常性晕厥;2例仍不能明确晕厥原因。提示ILR诊断晕厥的效率为80%。10例依据ILR监测结果得到相应治疗,晕厥发作减少或消失。结论ILR用于诊断不明原因晕厥和先兆晕厥安全、高效、长程,可证实或排除患者的部分晕厥或近似晕厥系心律失常所致;具有微创、简单、监测期长、信息量大等优点,可作为现有晕厥诊断方法的重要补充。加强患者的依从性和动态优化工作参数,将进一步提高ILR的诊断价值。     

Significance of tilt table testing in patients with suspected arrhythmic syncope and negative electrophysiologic study

BACKGROUND: The diagnostic significance of a tilt table test (TTT) in patients with a suspected arrhythmic etiology for syncope and negative electrophysiologic study (EPS) has not been previously assessed comparing the TTT results with the findings of prolonged monitoring using an implantable loop recorder (ILR). We sought to assess the diagnostic yielding of TTT in patients with suspected arrhythmic syncope and negative EPS. METHODS AND RESULTS: In 81 patients with suspected arrhythmic etiology for syncope and negative EPS, TTT was performed and an ILR implanted regardless the results of TTT. TTT was positive in 38 patients. During follow-up, syncope or presyncope recurred in 32 patients (39.5%). No differences were found in recurrence rates in patients with positive and negative TTT (31.5% vs 46.5%, P = ns). According to rhythm registered during ILR activation, mechanisms of syncopal events were classified as: arrhythmic (atrioventricular [AV] block and ventricular tachycardia; n = 18), neurally mediated (sinus bradycardia and sinus pause; n = 9), and indeterminate (normal sinus rhythm; n = 5). There was no statistical association between the results of TTT and the mechanism of syncope. CONCLUSIONS: In patients with a suspected arrhythmic etiology for syncope and a negative EPS, TTT is of little value to predict the mechanism of syncope and the ILR implantation seems to be a useful and safe diagnostic strategy.     

Usefulness of implantable loop recorders in office-based practice for evaluation of syncope in patients with and without structural heart disease

Early use of an implantable loop recorder for evaluating unexplained syncope in an office-based electrophysiology practice is an effective approach in patients with and without structural heart disease. Documentation of rhythm with an implantable loop recorder at the time of symptoms is possible in approximately 50% and 80% of patients in both groups after 1 and 2 years of follow-up, respectively.     

Efficacy of Midodrine Hydrochloride in Neurocardiogenic Syncope Refractory to Standard Therapy

Midodrine for Refractory Neurocardiogenic Syncope. introduction : Some patients with neurocardiogenic syncope continue to have recurrent syncope or presyncope despite the use of currently available drug therapy. The purpose of this study was to determine whether midodrine hydrochloride, a selective adrenergic agonist, could he effective in patients resistant to, or intolerant of, currently used medications in the treatment of neurocardiogenic syncope.
Methods and Results : Eleven patients with a history of recurrent syncope or presyncope in whom hypotension with syncope or presyncope could be provoked during head-up tilt testing were included. There were 4 men and 7 women with a mean age (± SD) age of 34 ± 13 years. In all patients, standard therapy with beta-adrenergic receptor blocking agents, ephedrine, theophylline, disopyramide, fludrocortisone, and sertraline hydrochloride, was either ineffective, poorly tolerated, or contraindicated. Midodrine was initially administered orally at a dose of 2.5 mg three times daily. After adjustment of dosage over 2 to 4 weeks, patients were followed-up clinically. Midodrine was discontinued in one patient because of side effects. Frequency of syncope or presyncope during the 3 months prior to starting treatment was compared during a mean follow-up of 17 ± 4 weeks after starting treatment with midodrine. There was significant (P < 0.01) reduction in syncopal and presyncopal episodes on midodrine. Five patients had complete resolution of symptoms, while four patients had significant improvement. Symptoms did not improve in one patient.
Conclusions : Midodrine hydrochloride can he effective in preventing recurrent symptoms in selected patients with neurocardiogenic syncope unresponsive to, or intolerant of, standard drug therapy.     

Generalized tonic-clonic seizures detected by implantable loop recorder devices: Diagnosing more than cardiac arrhythmias

BACKGROUND: Both syncope and seizures are important causes of recurrent, unexplained episodes of loss of consciousness. Implantable loop recorders have identified serious arrhythmias in patients with repeated syncope; however, implantable loop recorder detection of seizures is less well established. OBJECTIVES: The purpose of this study was to provide in-depth analysis of a characteristic myopotential pattern recorded by implantable loop recorders during generalized tonic-clonic seizures. METHODS: Fourteen patients with refractory, video-EEG-documented epilepsy (complex partial, atonic, tonic, or generalized tonic-clonic seizures) underwent implantable loop recorder placement as part of a study protocol evaluating cardiac rhythm abnormalities in patients at high risk for sudden unexpected death in epilepsy. RESULTS: Twelve generalized tonic-clonic seizure episodes were detected by the implantable loop recorder in six patients. Implantable loop recorder and EEG recordings of generalized tonic-clonic seizures were identical and revealed a tonic phase (sustained, rapid, high-frequency myopotentials) transitioning to a clonic phase (periodic bursts of high-frequency myopotentials with a decelerating burst frequency from 3-6 Hz to 1-2 Hz) prior to seizure termination. With the nonprogrammable bandpass filter of 0.85 to 32 Hz in the implantable loop recorder, all generalized tonic-clonic seizure episodes had escaped automatic detection and required activation by family members. None of the 76 nongeneralized tonic-clonic seizure episodes recorded on the implantable loop recorder in the 14 patients exhibited the stereotypical tonic-clonic pattern that defines generalized seizures. CONCLUSION: Recognizing this specific myopotential pattern on an implantable loop recorder might help diagnose generalized tonic-clonic seizures as a cause of recurrent, unexplained episodes of loss of consciousness. Having a programmable bandpass filter in the implantable loop recorder might increase its diagnostic yield for such patients.     

Initial clinical experience with implantable loop recorders.

The purpose of this study was to review the initial experience of a university hospital with Implantable Loop Recorders (ILR) for diagnosis of recurrent unexplained syncope or presyncope. Twelve patients with syncope or presyncope of unknown etiology (who had a negative tilt table test, electrophysiologic study, and neurologic work-up) underwent implantation of ILR. All implants were performed using the Reveal ILR (Medtronic AVE, Santa Rosa, California). The 8 cc device is 61 mm long, 19 mm wide, 8 mm thick and weighs 17 grams. It has 18 months of battery life and has 2 electrodes with 38.5 mm spacing. The device is nonvascular and is implanted approximately 2 fingerbreadths below the clavicle in a subcutaneous pocket (1.5 inches long) and is secured via polydacron suture to the pre-pectoral fascia/pectoralis muscle. Twelve patients with a mean age of 61 +/- 22 years received the ILR. Ten patients had syncope and 2 had presyncope. Three patients had coronary artery disease and 2 had dilated cardiomyopathy. ILRs were implanted for a mean follow-up period of 7.2 +/- 5.8 months (range, 1 day to 18 months). Two patients still continue to be monitored at the time of this report. The mean number of events prior to ILR was 6.0 +/- 5.4. Eight patients (66%) had recurrent syncope after implantation. One patient was not available for follow-up. There were no significant complications from the implant. In 5/12 patients (42%), the ILR helped to diagnose the etiology of the syncopal episode. Syncope was secondary to asystole in three patients, junctional bradycardia in another patient, and seizure activity in a fifth patient (high-frequency noise recorded on the electrocardiogram during sinus rhythm). The 4 patients with ILR-documented bradyarrhythmias underwent permanent pacemaker implantation and are alive and well. ILR implantation is a simple, useful and safe method in assisting with the diagnosis of recurrent unexplained syncope or presyncope after an inconclusive electrophysiologic and neurologic evaluation.     

Digital implantable loop recorders in the investigation of syncope in children: Benefits and limitations

BACKGROUND: Conventional diagnostic methods for detecting arrhythmogenic causes of syncope in children are poor. Digital implantable loop recorders are of proven value in adults. OBJECTIVES: The purpose of this study was to evaluate digital implantable loop recorders in the investigation of syncope in children. METHODS: We reviewed the clinical and technical records of 18 consecutive patients (6 female and 12 male; age 相似文献   

Efectividad y seguridad de la monitorización a distancia de los pacientes portadores de Holter insertable

Introduction and objectivesImplantable loop recorders have proven efficacy in the study of patients with syncope and palpitations. Remote monitoring of patients with pacemakers and implantable cardioverter-defibrillators has been shown to be safe and effective. The purpose of this study was to analyze the safety and effectiveness of remote monitoring in patients with an implantable loop recorder.MethodsRetrospective observational study in which 109 patients with an implantable loop recorder were analyzed and 2 population groups were compared: 1 receiving conventional follow-up consisting of 3-monthly office visits (41 patients) and 1 with remote monitoring via monthly telephone transmissions and yearly visits (68 patients). The mean follow-up was 64 weeks (range, 0.57-164.57 weeks). The study analyzed diagnosis of a significant event, defined as any event that led to a therapeutic approach and explained the symptoms leading to the implant, as well as the mean time from implant to diagnosis and the specific treatment.ResultsA significant event was diagnosed in 82.6% of patients; of these, 54.4% had a normal electrocardiogram; 26.7%, asystole; 15.6%, tachycardia, and 3.3%, bradycardia. The mean time from implant to diagnosis was 260 days (range, 5-947 days) in conventional follow-up, compared with 56 days (range, 0-650 days) in patients with remote monitoring (P<.01), which led to targeted treatment in this group 187 days earlier, on average, with no secondary complications.ConclusionsRemote monitoring of patients with an implantable loop recorder can significantly shorten the time to diagnosis and targeted treatment, without adversely affecting patient safety.Full English text available from: www.revespcardiol.org/en     

The Utility of Holter Monitoring Compared to Loop Recorders in the Evaluation of Syncope and Presyncope

Background: Holter monitoring is frequently used to assess patients with syncope, but rarely provides a diagnosis. Newer loop recorders provide the opportunity for prolonged electrocardiographic monitoring to enhance diagnostic yield. Methods: The results of 232 Holter monitors and 81 loop recordings performed for the investigation of syncope or presyncope were reviewed for indication, patient demographics, and presence and type of symptoms and/or arrhythmias. The results were classified as (1) symptom‐arrhythmia correlation, (2) clinically useful information (group 1 plus those excluding arrhythmic syncope, and those demonstrating asymptomatic serious arrhythmias) and (3) unhelpful (asymptomatic and no serious arrhythmias). Results: Loop recorders provided a symptom‐arrhythmia correlation in 11.1% of patients compared to only 0.4% in the Holter group (P < 0.0001). Clinically useful information was obtained in 54.3% of loop patients compared to 27.6% in the Holter group (P < 0.0001). Technical problems occurred in 0.4% of the Holter patients and in 3.7% of loop patients (P = 0.05). Classification was difficult in seven patients in the Holter group; two experienced symptoms during sinus rhythm but also had a serious asymptomatic arrhythmia, and five patients had 6–10 beats of asymptomatic ventricular tachycardia at a rate < 160 beats/min. Conclusion: Loop recording was well tolerated and superior to Holter monitoring in providing a symptom‐arrhythmia correlation or clinically useful information in patients with syncope and presyncope. An initial approach with a loop‐recording device should be employed in these patients.     

Use of the implantable loop recorder in patients with unexplained syncope

Syncope is a complex clinical syndrome with multiple etiologies that can be very difficult to diagnose. The major obstacles to diagnosis are the periodic and unpredictable nature of events and the high spontaneous remission rate. Conventional testing is often unproductive in patients when initial non-invasive testing is negative, particularly when a paroxysmal ar-rhythmia is suspected. Holter monitoring is often employed initially, with limited utility. Holter monitoring provides a rhythm profile, but rarely achieves the gold standard of a symptom rhythm correlation. The external loop re-corder extends the period of monitoring, enhancing the diagnostic yield to as high as 60% in patients with symptoms likely to recur during a month of device use. Finally, implantable loop recorders further extend the ability to monitor cardiac patients, enhancing the diagnostic yield to as high as 85% in difficult to diagnose syncope. Several recent studies suggest that prolonged monitoring with an implantable loop recorder has a role in patients with syncope and conduction disturbances, negative tilt testing, unexplained seizures and may be superior to conventional testing with tilt and electrophysiologic studies in select patients.     

Long-term outcome of patients with syncope associated with coronary artery disease and a nondiagnostic electrophysiologic evaluation

Syncope in the patient with structural heart disease and a nondiagnostic noninvasive workup is a generally accepted indication for an invasive electrophysiologic study. However, if the electrophysiologic evaluation is not highly sensitive, arrhythmic causes of syncope may not be discovered. In these patients, recurrent syncope and even sudden death may be observed at follow-up. Thus, we evaluated long-term follow-up in 68 consecutive patients who presented with syncope, coronary artery disease, and who had a negative invasive electrophysiologic evaluation. At a mean follow-up of 30 +/- 18 months (range 1 to 65), there have been 2 sudden deaths and 1 episode each of ventricular fibrillation and ventricular tachycardia in patients treated with an implantable cardioverter-defibrillator. All 4 arrhythmias occurred in patients with left ventricular fractions < or = 25%. Seventeen patients had recurrent presyncope or syncope. Bradycardia causing syncope was found in 8 of these patients. A bundle branch block at the initial evaluation predicted for the occurrence of bradycardia at follow-up. We conclude that in patients with coronary artery disease and syncope, noninducibility at electrophysiologic study predicts a lower risk of sudden death and ventricular arrhythmias. However, in patients with a reduced ejection fraction, the risk of sudden death and ventricular arrhythmias remains up to 10%/year and these patients may warrant treatment with implantable cardioverter-defibrillators. Recurrent syncope is common, and frequently a bradyarrhythmia is found to be the cause. Treatment of selected patients (especially those with bundle branch blocks) with permanent pacemakers may be justified.     

Comparison of automatic and patient-activated arrhythmia recordings by implantable loop recorders in the evaluation of syncope

The implantable loop recorder (ILR) has become an important tool for evaluating patients with recurrent syncope. Second generation ILRs have the ability to record events either automatically (auto activated) or by manual activation (patient activated). In an attempt to evaluate the relative utility of the auto-activation feature, this study stratified ILR events based on a grading system designed to classify detected arrhythmias in terms of the likelihood that they provide a diagnostic basis for syncope. Data from 50 patients (27 men, mean age 64 +/- 22 years) who underwent ILR implantation for investigation of recurrent syncope were assessed. The arrhythmia syncope grading system used 5 levels, ranging from grade 0 (rhythm recorded during syncope) to grade IV (rhythm unlikely to provide a diagnostic basis for syncope). Thirty-six patients (72%) demonstrated > or =1 auto-activated or patient-activated recording during a follow-up of 14.3 +/- 7.9 months. Of the total of 529 recordings, 223 (194 after auto activation [86.9%]) from 30 patients showed a rhythm abnormality. Auto activation was more effective for documenting arrhythmias that were recorded during syncope or those with highest probability of providing a syncope diagnosis (grade 0 or I arrhythmias: auto activated, 19 patients, patient activated, 3 patients). Times from ILR implantation to first grade 0 and grade I arrhythmias were 13.4 and 7.8 months, respectively. The ILR auto-activation feature proved effective in providing a high probability basis for syncope (196 arrhythmia recordings [87.1%] in 27 patients) and enhanced the diagnostic effectiveness of the device compared with patient activation alone (29 arrhythmia recordings [12.9%] in 6 patients).